CHMP backs Zepzelca plus Tecentriq for first-line ES-SCLC
A positive CHMP opinion has moved Zepzelca (lurbinectedin) plus Tecentriq (atezolizumab) a step closer to broader European use as a first-line maintenance regimen for adults with extensive-stage small cell lung cancer after induction chemoimmunotherapy. The recommendation centers on patients whose disease has not progressed after initial treatment with atezolizumab, carboplatin, and etoposide, and it builds on phase 3 data suggesting the doublet can extend survival compared with atezolizumab maintenance alone. (pubmed.ncbi.nlm.nih.gov)
The background here matters. Tecentriq already has an established role in first-line ES-SCLC in Europe in combination with carboplatin and etoposide, based on earlier regulatory action. Lurbinectedin, meanwhile, has been developing from a later-line SCLC therapy into a candidate for earlier use, supported by orphan-drug history in Europe and a broader strategy by PharmaMar and its regional partners, including Immedica, to expand access across Europe and other territories. (roche.com)
The pivotal evidence came from the randomized, multicenter, open-label phase 3 IMforte trial. At the July 29, 2024 data cutoff, progression-free survival favored lurbinectedin plus atezolizumab, with a hazard ratio of 0.54, and overall survival also improved, with a hazard ratio of 0.73. Median overall survival was 13.2 months in the combination arm versus 10.6 months with atezolizumab alone. The tradeoff was toxicity: grade 3-4 adverse events were reported in 38% of patients receiving the combination and 22% of those receiving atezolizumab alone. (pubmed.ncbi.nlm.nih.gov)
Company statements framed the results as clinically meaningful and potentially practice changing. Roche said in June 2025 that the regimen significantly extended survival in ES-SCLC, while PharmaMar had earlier described the IMforte results as statistically significant for both progression-free and overall survival. Coverage from oncology trade outlets and meeting reports echoed that this could represent a new maintenance option in a disease where durable gains have been hard to achieve. (roche.com)
There’s also a broader regulatory arc. The FDA approved the combination in October 2025 for first-line maintenance in adults with ES-SCLC whose disease had not progressed after induction therapy, giving the regimen an important precedent in a major market. EMA’s public tracking page for medicines under evaluation shows that extension-of-indication procedures continue to move through CHMP review, and a positive CHMP opinion is typically the final scientific hurdle before a European Commission decision. (roche.com)
Why it matters: For veterinary professionals, this is less about direct species crossover and more about where oncology is heading. Human oncology continues to push effective agents into earlier-line and maintenance settings, using incremental survival gains to redefine standard of care in fast-moving cancers. That pattern often influences translational thinking, trial design, biomarker strategy, and expectations around tolerability monitoring. The IMforte data also reinforce a recurring lesson: better disease control may come with higher rates of clinically significant adverse events, making supportive care and patient selection central to adoption. (pubmed.ncbi.nlm.nih.gov)
It’s also a reminder that market access is layered. Even if the European Commission converts the CHMP recommendation into approval, uptake will still depend on national reimbursement, local guideline updates, and clinician comfort with the added toxicity burden. In regions where Immedica holds commercial rights, the company’s role will likely be less about generating new efficacy data and more about execution, access, and education. (immedica.com)
What to watch: The immediate next milestone is the European Commission’s final decision, followed by label language, reimbursement negotiations, and any new guideline endorsements that determine how quickly the combination moves into routine ES-SCLC care in Europe. (ema.europa.eu)